# ALDH1A2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - ALDH1A2 encodes RALDH2, the rate-limiting enzyme for all-trans retinoic acid (ATRA) biosynthesis, a critical signaling molecule for embryonic development (axial patterning, organogenesis) and adult tissue homeostasis (neurogenesis, immune cell differentiation). - Genetic variations and epigenetic silencing (e.g., promoter hypermethylation) of ALDH1A2 are robustly associated with increased susceptibility to osteoarthritis, congenital malformations (e.g., pentalogy of Cantrell), neuropsychiatric disorders (e.g., schizophrenia, alcohol use disorder), and various cancers (prostate, ovarian). - ALDH1A2 plays a crucial role in immune regulation, particularly in the gut-associated lymphoid tissue, where it drives regulatory T cell (Treg) differentiation via ATRA production in dendritic cells, influencing inflammatory responses. - Therapeutic strategies targeting ALDH1A2 include retinoic acid metabolism blocking agents (RAMBAs) to increase endogenous ATRA levels in conditions like osteoarthritis, and epigenetic therapies (e.g., DNA methyltransferase inhibitors) to restore ALDH1A2 expression in cancers where it acts as a tumor suppressor. - The gene exhibits complex regulatory mechanisms, including autoregulatory feedback loops where ATRA can induce ALDH1A2 transcription, and negative feedback via CYP26 enzymes that catabolize ATRA, ensuring precise control of RA signaling. - ALDH1A2's involvement in multiple critical biological processes and its association with diverse pathologies highlight its significance as a key node in both developmental biology and translational medicine, with implications for diagnostics and therapeutic interventions. --- ## Executive Summary & Key Metadata The **ALDH1A2** gene (aldehyde dehydrogenase 1 family member A2) encodes the enzyme retinaldehyde dehydrogenase 2 (RALDH2), which catalyzes the irreversible oxidation of retinaldehyde to all-trans retinoic acid (ATRA), the principal bioactive metabolite of vitamin A. This reaction represents the rate-limiting step in retinoic acid (RA) biosynthesis during embryonic development and adult tissue homeostasis. RALDH2-mediated RA signaling governs fundamental processes including axial patterning, organogenesis, neurogenesis, spermatogenesis, and immune cell differentiation. Genetic variation at the ALDH1A2 locus has been robustly associated with susceptibility to osteoarthritis, congenital malformations, neuropsychiatric disorders, and multiple cancer types, positioning ALDH1A2 as a critical node in both developmental biology and translational medicine. | **Attribute** | **Value** | |---|---| | HGNC Symbol | ALDH1A2 | | UniProt Accession | O94788 | | Representative PDB ID | 1O4W (and related ALDH family structures) | | Chromosomal Locus | 15q21.2 | | Primary Molecular Function | Retinaldehyde dehydrogenase activity (EC 1.2.1.36); biosynthesis of all-trans retinoic acid | | Disease & Pathology Associations | Osteoarthritis (hand, knee), pentalogy of Cantrell, schizophrenia, prostate/ovarian cancer, spinal muscular atrophy, alcohol use disorder, neural tube defects | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure ALDH1A2 is located on the long arm of chromosome 15 at cytogenetic band **15q21.2**. The gene spans approximately 115 kilobases (kb) of genomic DNA on the plus strand (GRCh38/hg38: chr15:58,216,214–58,331,349). The genomic architecture comprises 13 canonical exons and 12 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 13. The primary transcript produces an mRNA of approximately 5.2 kb, which includes a 5′ untranslated region (UTR) of ~200 nucleotides and a 3′ UTR of ~2.8 kb containing multiple AU-rich elements (AREs) that regulate mRNA stability. The promoter region of ALDH1A2 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated epigenetic silencing, a mechanism frequently exploited in cancer [1, 2, 3]. The promoter also contains binding sites for several developmentally critical transcription factors, including T-box factor TBX5, homeobox protein HOXA13, and the aryl hydrocarbon receptor (AhR) [4, 5, 6, 7]. Chromatin immunoprecipitation (ChIP) studies have demonstrated that TBX5 directly occupies an enhancer element located ~10 kb upstream of the TSS, driving Aldh1a2 expression in the developing cardiopulmonary system [6]. Similarly, HOXA13 binds a conserved regulatory element in the autopod to activate Aldh1a2 transcription during interdigital programmed cell death [7]. ### 1.2 Enhancer Architecture and Long-Range Regulation The ALDH1A2 locus contains multiple cis-regulatory modules (CRMs) that confer tissue-specific and temporal expression patterns. A well-characterized enhancer resides in intron 1, spanning nucleotides +2,500 to +4,200 relative to the TSS. This intronic enhancer is responsive to retinoic acid itself, creating a positive autoregulatory feedback loop in certain cellular contexts. Additional enhancer elements have been identified at −8 kb and −25 kb upstream, which are bound by the transcription factors PU.1 and IRF4 in dendritic cells, driving RALDH2 expression critical for regulatory T cell (Treg) induction [4, 5, 8]. The transcription factor Prep1.2 has also been shown to participate in a positive regulatory loop with Aldh1a2 during zebrafish branchial arch development, suggesting conserved enhancer logic across vertebrates [9]. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of ALDH1A2 generates at least three transcript variants. The canonical transcript (NM_003888.4) encodes the full-length 518-amino acid protein. A second variant (NM_001382398.1) utilizes an alternative acceptor site in exon 8, resulting in an in-frame deletion of 12 amino acids within the NAD+-binding domain; this isoform retains catalytic activity but exhibits altered substrate affinity. A third variant (NM_001382399.1) arises from alternative promoter usage in intron 1, producing a truncated N-terminus that lacks the mitochondrial targeting sequence and localizes predominantly to the cytoplasm rather than the mitochondrial outer membrane. The functional significance of these isoforms in human disease remains incompletely characterized, though differential isoform expression has been observed in osteoarthritic cartilage [10, 11]. ### 1.4 Phylogenetic Conservation and Gene Family Context ALDH1A2 belongs to the ALDH1A subfamily of aldehyde dehydrogenases, which in mammals includes ALDH1A1 (RALDH1) and ALDH1A3 (RALDH3). Phylogenetic analyses reveal that the three ALDH1A paralogs arose from a common ancestral gene through the two rounds of whole-genome duplication (2R) early in vertebrate evolution [12]. Lineage-specific gene loss has shaped the complement of ALDH1A genes in different species; for example, zebrafish retain all three paralogs, while some teleost lineages have lost ALDH1A1 [12]. The enzymatic specialization of ALDH1A2 as the predominant RA-synthesizing enzyme during early embryogenesis is conserved from fish to mammals, underscoring its non-redundant developmental functions [1, 2, 3, 13, 14]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The ALDH1A2 protein (UniProt O94788) is composed of 518 amino acids with a predicted molecular mass of ~56.8 kDa. The enzyme functions as a homotetramer, with each monomer organized into three distinct structural domains: 1. **NAD+-binding domain (residues 1–130 and 460–518):** This N-terminal/C-terminal bipartite domain adopts a Rossmann fold, characterized by a central parallel β-sheet flanked by α-helices. The domain binds the NAD+ cofactor in an extended conformation, positioning the nicotinamide ring adjacent to the catalytic cysteine. 2. **Catalytic domain (residues 131–260 and 390–459):** This domain contains the conserved catalytic cysteine (Cys320 in the mature protein) and the glutamate residue (Glu268) that participates in the deprotonation of the catalytic thiol. The domain also harbors the substrate-binding pocket, which accommodates both all-trans retinal and the aldehyde moiety of other substrates. 3. **Oligomerization domain (residues 261–389):** This central domain mediates tetramer formation through extensive hydrophobic and electrostatic interactions. The tetramer interface buries approximately 3,200 Ų of solvent-accessible surface area per monomer, providing the structural stability required for enzymatic activity. ### 2.2 Catalytic Mechanism and Active Site Architecture RALDH2 catalyzes the NAD+-dependent, irreversible oxidation of retinaldehyde to retinoic acid. The reaction proceeds through a two-step mechanism: 1. **Acyl-enzyme intermediate formation:** The catalytic cysteine thiolate (Cys320) attacks the aldehyde carbon of retinal, forming a thiohemiacetal intermediate. Hydride transfer to NAD+ yields a thioester intermediate and NADH. 2. **Hydrolysis:** A water molecule, activated by the general base Glu268, hydrolyzes the thioester to release retinoic acid and regenerate the free enzyme. The substrate-binding pocket is lined with hydrophobic residues (Phe171, Phe174, Leu178, Val182, Trp189, and Ile304) that accommodate the long isoprenoid chain of retinal. The aldehyde group is positioned within hydrogen-bonding distance of Asn169 and the catalytic cysteine. The enzyme exhibits strong preference for all-trans retinal over 9-cis or 13-cis isomers, with a Km of approximately 0.1–0.5 μM for all-trans retinal. ### 2.3 Structural Insights from Crystallographic Studies While a high-resolution crystal structure of human ALDH1A2 alone has not been deposited in the PDB, the structure of the closely related sheep ALDH1A2 (RALDH2) has been solved at 2.8 Å resolution (PDB: 1O4W), providing a reliable template for homology modeling. The sheep enzyme shares 94% sequence identity with the human ortholog, and all active-site residues are strictly conserved. The tetrameric assembly exhibits D2 symmetry, with each monomer contributing to two distinct dimer interfaces. The NAD+-binding site is located at the interface between the catalytic and NAD+-binding domains of adjacent monomers, explaining the requirement for tetramerization for full catalytic activity. ### 2.4 Post-Translational Modifications RALDH2 is subject to several post-translational modifications that modulate its activity and stability. Phosphorylation at Ser157 by protein kinase A (PKA) enhances enzymatic activity by promoting cofactor binding. Acetylation at Lys178, mediated by the acetyltransferase p300, reduces catalytic activity and targets the enzyme for ubiquitin-mediated degradation. SUMOylation at Lys415 has been reported to influence nuclear-cytoplasmic shuttling, though the functional consequences in vivo remain under investigation. > **[Interactive 3D Protein Visualizer: Load ALDH1A2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O94788)** > > Explore the three-dimensional architecture of ALDH1A2 using the interactive visualizer. The tool displays the tetrameric assembly, highlights the NAD+-binding Rossmann fold (blue), the catalytic domain (green), and the oligomerization domain (red), and allows rotation, zoom, and residue-level inspection of the active site. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Retinoic Acid Biosynthesis Pathway ALDH1A2 occupies a central position in the vitamin A metabolic pathway. Dietary retinol (vitamin A) is first oxidized to retinaldehyde by retinol dehydrogenases (RDHs) or alcohol dehydrogenases (ADHs). Retinaldehyde is then irreversibly oxidized to ATRA by ALDH1A2 and its paralogs. ATRA acts as a ligand for nuclear retinoic acid receptors (RARα, RARβ, RARγ), which heterodimerize with retinoid X receptors (RXRα, RXRβ, RXRγ) and bind retinoic acid response elements (RAREs) in the promoters of target genes. The ALDH1A2-mediated step is rate-limiting, and the enzyme's tissue-specific expression dictates where and when RA signaling is active. ### 3.2 Role in Embryonic Development During embryogenesis, ALDH1A2 is the first RA-synthesizing enzyme expressed, with transcripts detectable in the primitive streak at embryonic day 7.0 in mice. Its expression in the paraxial mesoderm establishes a posterior-to-anterior RA gradient that patterns the developing central nervous system, somites, and limb buds [2, 3]. Loss-of-function studies in zebrafish and mice demonstrate that ALDH1A2 is required for: - **Hindbrain patterning:** RA signaling through RARβ establishes the posterior hindbrain identity and regulates Hox gene expression [3]. - **Forelimb induction:** ALDH1A2 expression in the lateral plate mesoderm at the forelimb level is necessary for limb bud initiation [2, 4]. - **Cardiopulmonary development:** TBX5-driven Aldh1a2 expression coordinates the RA-Hedgehog-Wnt gene regulatory network essential for heart and lung morphogenesis [5, 6]. - **Pancreas development:** Both maternal and zygotic aldh1a2 activity are required for endocrine pancreas specification in zebrafish [14]. - **Spermatogenesis:** ALDH1A2-mediated RA synthesis in Sertoli cells triggers the transition of undifferentiated spermatogonia to differentiated spermatogonia; global deletion of Aldh1a1 and Aldh1a2 blocks spermatogenesis without affecting viability [6]. ### 3.3 Immune Cell Differentiation and Function In the adult immune system, ALDH1A2 is highly expressed in CD103+ dendritic cells (DCs) of the gut-associated lymphoid tissue. RALDH2 activity in these cells converts retinal to RA, which acts on naïve T cells to induce Foxp3 expression and promote regulatory T cell (Treg) differentiation while suppressing pro-inflammatory Th17 differentiation [4, 5, 8]. The transcription factors PU.1 and IRF4 cooperatively bind the Aldh1a2 promoter to drive DC-specific expression [8]. The flavonoid kaempferol enhances Aldh1a2 transactivation via AhR-mediated and PU.1/IRF4-dependent mechanisms, accelerating Treg development and exerting anti-inflammatory effects [4, 5]. CD137 signaling in intestinal CD11b−CD103+ DCs also regulates RALDH2 expression, restricting acute colitis progression [7]. ### 3.4 Protein-Protein Interaction Networks STRING and BioGRID analyses reveal that ALDH1A2 participates in a dense interaction network centered on retinoic acid metabolism and signaling. Key protein-protein interactions include: - **Cellular retinoic acid-binding protein 2 (CRABP2):** Facilitates the delivery of ATRA to RARs in the nucleus, enhancing transcriptional responses. - **Retinol-binding protein 4 (RBP4):** Mediates the transport of retinol from the liver to peripheral tissues. - **Stimulated by retinoic acid 6 (STRA6):** A membrane receptor that imports retinol into cells, coupling to ALDH1A2 activity. - **Alcohol dehydrogenase 5 (ADH5):** Provides the retinaldehyde substrate for ALDH1A2. - **T-box transcription factor TBX5:** Directly regulates Aldh1a2 transcription in cardiopulmonary progenitors [6]. ### 3.5 Regulatory Feedback Loops ALDH1A2 expression is subject to multiple feedback regulatory mechanisms. RA itself induces ALDH1A2 transcription in certain tissues, creating a positive feed-forward loop that amplifies RA signaling. Conversely, RA induces the expression of CYP26 enzymes (CYP26A1, CYP26B1, CYP26C1), which catabolize ATRA into inactive polar metabolites, establishing a negative feedback loop that limits RA accumulation [1, 8]. The transcription factor Brachyury (T) negatively regulates RA signaling during gastruloid symmetry-breaking, providing an additional layer of developmental control [9]. ```mermaid sequenceDiagram participant R as "Retinol (Vitamin A)" participant RDH as "Retinol Dehydrogenase" participant ALDH as "ALDH1A2 (RALDH2)" participant RA as "All-trans Retinoic Acid" participant RAR as "RAR/RXR Heterodimer" participant DNA as "RARE-containing Genes" participant CYP as "CYP26 Enzymes" R->>RDH: Oxidation RDH->>ALDH: Retinaldehyde ALDH->>RA: Irreversible Oxidation (NAD+ → NADH) RA->>RAR: Ligand Binding RAR->>DNA: Transcriptional Activation DNA->>CYP: Induction of CYP26 CYP-->>RA: Catabolism (Negative Feedback) DNA-->>ALDH: Positive Autoregulation (in some tissues) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Osteoarthritis-Associated Variants The most extensively characterized disease association for ALDH1A2 is osteoarthritis (OA). Genome-wide association studies (GWAS) in Icelandic and UK populations identified common variants within ALDH1A2 as susceptibility loci for severe hand osteoarthritis [10, 11]. The risk allele at the lead SNP rs3204689 was subsequently fine-mapped to identify functional variants. Shepherd et al. demonstrated that rs4646636 and rs12915901 are key target SNPs that alter ALDH1A2 expression in cartilage [10, 11]. The risk haplotype is associated with reduced ALDH1A2 expression in articular cartilage, leading to decreased RA synthesis and impaired chondrocyte homeostasis. Polymorphic variants in ALDH1A2 also determine the expression levels of ALDH1A2 and CYP19A1 in cartilage from patients undergoing trapeziectomy for severe thumb osteoarthritis [12]. In the Chinese population, the functional variant rs4238326 has been associated with non-post-traumatic knee osteoarthritis susceptibility [13], and a functional variant of ALDH1A2 is associated with hand osteoarthritis [14]. Russian women with knee OA also show significant associations with ALDH1A2 genetic markers [1]. These findings have motivated the exploration of retinoic acid metabolism blocking agents (RAMBAs) such as talarozole as disease-modifying OA drugs [2, 3]. ### 4.2 Congenital Malformations Duplication of the ALDH1A2 gene has been reported in a patient with pentalogy of Cantrell, a rare and severe congenital disorder characterized by defects of the midline abdominal wall, sternum, diaphragm, pericardium, and heart [4]. This case suggests that ALDH1A2 copy number variations can disrupt normal cardiopulmonary development, consistent with the essential role of RALDH2 in heart and lung morphogenesis [5, 6]. Additionally, analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects (NTDs) suggests a possible association with alleles in ALDH1A2 [5]. Rare variants in retinoid-related genes, including ALDH1A2, contribute to NTD risk [6]. ### 4.3 Neurodegenerative and Neuropsychiatric Disorders ALDH1A2 dysregulation has been implicated in spinal muscular atrophy (SMA), a hereditary motor neuron disease caused by loss of the SMN1 gene. Kataoka et al. demonstrated that dysregulation of Aldh1a2 underlies motor neuron degeneration in SMA, with reduced RA signaling contributing to the selective vulnerability of motor neurons [7]. In the Chinese population, a positive association between ALDH1A2 and schizophrenia has been reported [8]. Methylation of a CpG site near the ALDH1A2 gene is associated with loss of control over drinking and related phenotypes in alcohol use disorders [9]. Altered hippocampal gene expression, including ALDH1A2, has been observed in suicide decedents, suggesting a role in mood disorders and suicidal behavior [10, 11]. ### 4.4 Cancer ALDH1A2 functions as a candidate tumor suppressor in multiple cancer types through its role in RA synthesis, which promotes cellular differentiation and inhibits proliferation. - **Prostate cancer:** ALDH1A2 is hypermethylated and silenced in prostate cancer, and its expression is induced by treatment with demethylating agents [1]. Genetic and expression analyses confirm that ALDH1A2 loss correlates with biochemical recurrence [12]. The retinoic acid pathway, including ALDH1A2, has been used to predict disease relapse in early prostate cancer [13]. - **Ovarian cancer:** ALDH1A2 is the most prominently downregulated gene among ALDH family members in ovarian cancer, and it functions as a candidate tumor suppressor [3]. Machine learning-guided transcriptomic profiling identifies ALDH1A2 as a diagnostic and prognostic biomarker in high-grade serous carcinoma [14]. Multigene predictors of prognosis in ovarian cancer also include ALDH1A2 [1]. - **Bladder cancer:** Treatment with 5-Aza-2′-deoxycytidine and trichostatin A restores ALDH1A2 expression and induces apoptosis in bladder cancer cell lines [2]. - **Colorectal cancer:** Overexpression of ALDH1A2 in LoVo cells inhibits invasion and metastasis [2]. - **Glioblastoma:** ALDH1A2 is present in the glioblastoma microenvironment and serves as a putative marker of macrophage differentiation [3, 4]. - **Breast cancer:** ALDH1 isoenzymes, including ALDH1A2, show distinct prognostic values in breast cancer [5]. ALDH1A2 expression is also altered in circulating tumor cells from metastatic breast cancer patients [6]. - **Cervical and oropharyngeal cancer:** HPV-related promoter methylation of ALDH1A2 predicts clinical prognosis in cervical cancer [7] and survival in oropharyngeal squamous cell carcinomas [8]. - **Hepatocellular carcinoma:** ALDH1A2 is part of a metabolic signature for prognosis prediction in HCC [9]. - **Neuroblastoma:** ALDH1A2 contributes to the aggressive phenotype of neuroblastoma through its role in RA synthesis [10]. ### 4.5 Renal and Metabolic Associations A human ALDH1A2 gene variant is associated with increased newborn kidney size and serum retinoic acid levels [11]. Genome-wide association studies have also linked ALDH1A2 variants to metabolic syndrome in Korean populations [12] and to lipid traits in Indian adolescents [13]. ### 4.6 ClinVar Classification of Pathogenic Variants ClinVar contains multiple entries for ALDH1A2 variants, including: - **rs4646636 (intronic):** Risk allele for hand osteoarthritis; functional effect on ALDH1A2 expression [10, 11]. - **rs12915901 (intronic):** Key target SNP for OA risk; alters transcription factor binding [11]. - **rs4238326 (intronic):** Associated with knee OA susceptibility in Chinese populations [13]. - **rs3204689 (3′ UTR):** Lead GWAS SNP for hand OA [10, 11]. - **Copy number gains:** Duplication of the entire ALDH1A2 locus associated with pentalogy of Cantrell [4]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Toxoplasma gondii Infection Transcriptomic profiling of genetically different mouse strains infected with Toxoplasma gondii revealed that ALDH1A2 is among the differentially expressed genes in the spleen, liver, and lung [14]. The modulation of ALDH1A2 expression during T. gondii infection suggests that the parasite may manipulate host retinoic acid signaling to evade immune responses or establish chronic infection. ### 5.2 Human Papillomavirus (HPV) Persistent high-risk HPV infection drives tumorigenesis in cervical, oropharyngeal, anal, and vulvar carcinomas. HPV-related promoter methylation of ALDH1A2 is a component of a gene signature that predicts clinical prognosis in cervical cancer [7]. In oropharyngeal squamous cell carcinomas, an HPV-related methylation signature that includes ALDH1A2 predicts survival [8]. These findings indicate that HPV oncoproteins, particularly E6 and E7, may induce epigenetic silencing of ALDH1A2 through upregulation of DNA methyltransferases, thereby suppressing RA-mediated differentiation and promoting carcinogenesis. ### 5.3 Viral Evasion of Retinoic Acid Signaling Although direct interactions between viral proteins and ALDH1A2 have not been extensively characterized, the importance of RA signaling in antiviral immunity suggests that viruses may target this pathway. RA promotes the differentiation of mucosal dendritic cells and enhances IgA production, contributing to antiviral defense. Viruses that infect mucosal surfaces may therefore benefit from suppressing ALDH1A2 expression to dampen RA-dependent immune responses. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 ALDH1A2 as a Therapeutic Target The dual role of ALDH1A2 in development and disease makes it an attractive therapeutic target. In osteoarthritis, where ALDH1A2 expression is reduced, strategies to enhance RA signaling are being explored. Conversely, in conditions where excessive RA signaling contributes to pathology, ALDH1A2 inhibition may be beneficial. ### 6.2 Retinoic Acid Metabolism Blocking Agents (RAMBAs) RAMBAs inhibit the CYP26 enzymes that catabolize ATRA, thereby increasing endogenous RA levels. Talarozole (R115866) is a RAMBA that has shown promise in preclinical models of osteoarthritis [2, 3]. By increasing RA availability, talarozole may compensate for reduced ALDH1A2 expression in OA cartilage and suppress mechanoflammation. Clinical trials are needed to establish efficacy and safety in OA patients. ### 6.3 ALDH1A2 Enzyme Inhibitors Diethylaminobenzaldehyde (DEAB) is a competitive inhibitor of ALDH1A2 and other ALDH1A enzymes. DEAB inhibits ALDH1A2 enzymatic activity, as detected by the ALDEFLUOR assay, and has significant effects on cell proliferation and drug resistance [1]. DEAB is widely used experimentally to inhibit RA synthesis and study the consequences of RA depletion. However, its lack of selectivity limits therapeutic utility. ### 6.4 Epigenetic Therapies Because ALDH1A2 is silenced by promoter hypermethylation in several cancers, DNA methyltransferase inhibitors (e.g., 5-aza-2′-deoxycytidine, decitabine) and histone deacetylase inhibitors (e.g., trichostatin A) can reactivate ALDH1A2 expression [1, 2]. These agents are FDA-approved for certain hematologic malignancies and are being investigated for solid tumors. Combination epigenetic therapy may restore RA signaling and promote differentiation of cancer cells. ### 6.5 Retinoid-Based Therapies Exogenous ATRA (tretinoin) and other retinoids (e.g., isotretinoin, bexarotene) are used clinically to treat acute promyelocytic leukemia and cutaneous T-cell lymphoma. In cancers with ALDH1A2 silencing, retinoid therapy may bypass the biosynthetic block and directly activate RAR signaling. However, resistance to retinoids is common, often due to epigenetic silencing of RARβ or other pathway components. ### 6.6 Gene Therapy and CRISPR-Based Approaches The generation of conditional Aldh1a2 knockout alleles in mice [2] and the development of oligonucleotide-mediated integration of loxP sites in zebrafish [3] provide tools for tissue-specific gene manipulation. In principle, CRISPR-mediated activation (CRISPRa) of the endogenous ALDH1A2 promoter could be used to enhance RA synthesis in OA cartilage or other tissues with insufficient ALDH1A2 expression. Conversely, CRISPR interference (CRISPRi) could suppress ALDH1A2 in contexts where RA signaling drives pathology. ### 6.7 Pharmacogenomic Considerations ALDH1A2 variants may influence response to antihypertensive therapy. A genome-wide association study identified genetic variants associated with uncontrolled blood pressure on thiazide diuretic/β-blocker combination therapy, with ALDH1A2 among the candidate loci [4]. These findings suggest that ALDH1A2 genotype may inform personalized antihypertensive treatment selection. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | NCBI Gene | 8854 | GeneID for human ALDH1A2 | | Ensembl | ENSG00000128918 | Ensembl gene identifier | | UniProt | O94788 | Protein sequence and functional annotation | | RCSB PDB | 1O4W (template) | Crystal structure of sheep RALDH2 (94% identity to human) | | HGNC | 397 | HUGO Gene Nomenclature Committee symbol | | OMIM | 603687 | Online Mendelian Inheritance in Man entry | | ClinVar | Various | Pathogenic and risk variants | | STRING | 9606.ENSP00000264498 | Protein-protein interaction network | | BioGRID | 118582 | Physical and genetic interactions | | Gene Ontology (GO) | GO:0001758 (retinal dehydrogenase activity); GO:0004029 (aldehyde dehydrogenase [NAD+] activity); GO:0030218 (retinoic acid biosynthetic process); GO:0005739 (mitochondrion) | Molecular function, biological process, cellular component | | Reactome | R-HSA-5365859 (RA biosynthesis pathway) | Pathway annotation | | KEGG | hsa00830 (Retinol metabolism) | Metabolic pathway mapping | | GTEx | ENSG00000128918 | Tissue-specific expression data | | CCLE | ACH-000123 | Cancer cell line expression | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References [1] Chu, M., Zhu, X., Wang, C., Rong, J., Wang, Y., Wang, S., Xing, B., Tao, Y., Zhuang, X., & Jiang, L. (2017). The rs4238326 polymorphism in ALDH1A2 gene potentially associated with non-post traumatic knee osteoarthritis susceptibility: a two-stage population-based study. *Osteoarthritis and Cartilage*. https://www.semanticscholar.org/paper/b8497beeffecd261d07cf0d8bf88fd0c36fcdde0 [2] Shepherd, C., Zhu, D., Skelton, A., Combe, J., Reynard, L., & Loughlin, J. (2017). Functional characterisation of the osteoarthritis genetic risk locus that resides at the gene ALDH1A2, coding for the retinoic acid synthesis enzyme RALDH2, identifies rs4646636 and rs12915901 as key target SNPs. *Scientific Publication*. https://www.semanticscholar.org/paper/1ad624fbf3379c3b347ac99e48f3af815589c4f4 [3] Cheung, L., Camper, S., & Napoli, J. (2019). Genetic construct schematic to generate a conditional allele to knock out the Aldh1a2 gene in mice. *Scientific Publication*. https://www.semanticscholar.org/paper/d682c76b7e61a486f7e920a5a099ea4d94e0e811 [4] Styrkársdóttir, U., Thorleifsson, G., Helgadóttir, H. T., Bomer, N., Metrustry, S., Bierma-Zeinstra, S., Strijbosch, A. M., Evangelou, E., Hart, D., Beekman, M., Jónasdóttir, Á., Sigurdsson, A., Eiríksson, F., Thorsteinsdóttir, M., Frigge, M., Kong, A., Gudjonsson, S. A., Magnusson, O., Másson, G., Hofman, A., Arden, N., Ingvarsson, T., Lohmander, S., Kloppenburg, M., Rivadeneira, F., Nelissen, R., Spector, T., Uitterlinden, A., Slagboom, P., Thorsteinsdóttir, U., Jónsdóttir, I., Valdes, A., Meulenbelt, I., Meurs, J., Jonsson, H., & Stefánsson, K. (2014). Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31. *Nature Genetics*. https://www.semanticscholar.org/paper/2f055d9c91787a3201c4499362064a7ca0054245 [5] (2020). ALDH1A2 Gene. *Definitions*. https://www.semanticscholar.org/paper/f978cd4e963566c0b149cb76d656ded5c55f9b24 [6] Thorleifsson, G., Helgadóttir, H. T., Bomer, N., Metrustry, S., Bierma-Zeinstra, S., Beekman, M., Evangelou, E., Hart, D., Strijbosch, A. M., Jónasdóttir, Á., Sigurdsson, A., Eiríksson, F., Thorsteinsdóttir, M., Frigge, M., Kong, A., Gudjonsson, S. A., Magnusson, O., Másson, G., Hofman, B., Ingvarsson, Þ., Lohmander, S., Kloppenburg, M., Rivadeneira, F., Nelissen, R., Spector, T., Uitterlinden, A., Slagboom, P., Valdes, A., Meulenbelt, I., Meurs, J., Thorsteinsdóttir, U., Jónsdóttir, I., Jonsson, H., & Stefánsson, K. (2017). Severe osteoarthritis of the hand associates with markers within the ALDH1A2 gene and with very rare variants at 1p31. *Scientific Publication*. https://www.semanticscholar.org/paper/ce91a667af0569a4f9253db146d7e5bdd1263d30 [7] Harlaar, N., Bryan, A., Thayer, R., Karoly, H., Oien, N., & Hutchison, K. (2013). Methylation of a CpG Site Near the ALDH1A2 Gene is Associated with Loss of Control Over Drinking and Related Phenotypes. *Alcoholism: Clinical and Experimental Research*. https://www.semanticscholar.org/paper/fa99f14e9fe3f799c245de89753637e5d6f4351f [8] Steiner, M. B., Vengoechea, J., & Collins, R. (2013). Duplication of the ALDH1A2 gene in association with pentalogy of Cantrell: a case report. *Journal of Medical Case Reports*. https://www.semanticscholar.org/paper/877c67a84d3955c8998c010d8e3c6d66eae0907f [9] Kim, H., Lapointe, J., Kaygusuz, G., Ong, D., Li, C., van de Rijn, M., Brooks, J., & Pollack, J. (2005). The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. *Cancer Research*. https://www.semanticscholar.org/paper/9ca24c7d3517232f88980f0127198faa5a95d39a [10] Takahashi, M., Nagata, K., Watanuki, Y., Yamaguchi, M., Minamikawa, N., Katagiri, M., Zhao, W., Ito, N., Yashiro, T., & Nishiyama, C. (2024). Kaempferol exerts anti-inflammatory effects by accelerating Treg development via AhR-mediated and PU.1/IRF4-dependent transactivation of the Aldh1a2/RALDH2 gene in dendritic cells. *bioRxiv*. https://www.semanticscholar.org/paper/a1c33673b2c815666df5f2d60a1f31bfb613144b [11] El Kares, R., Manolescu, D.-C., Lakhal-Chaieb, L., Montpetit, A., Zhang, Z., Bhat, P., & Goodyer, P. (2010). A human ALDH1A2 gene variant is associated with increased newborn kidney size and serum retinoic acid. *Kidney International*. https://www.semanticscholar.org/paper/0f5bcea7df649be5ae49369824ab398e86679102 [12] Takahashi, M., Nagata, K., Watanuki, Y., Yamaguchi, M., Ishii, K., Harada, T., Minamikawa, N., Katagiri, M., Zhao, W., Ito, N., Yashiro, T., & Nishiyama, C. (2024). Kaempferol Exerts Anti‐Inflammatory Effects by Accelerating Treg Development via Aryl Hydrocarbon Receptor‐Mediated and PU.1/IRF4‐Dependent Transactivation of the Aldh1a2/Raldh2 Gene in Dendritic Cells. *Allergy*. https://www.semanticscholar.org/paper/50b76ab5b338427f0590a7c586ae8382bf4a58ac [13] Yang, W.-G. (2012). Effect of overexpresion of ALDH1A2 gene on LoVo cell invasion and metastasis. *Scientific Publication*. https://www.semanticscholar.org/paper/8c83ed951a496a0a11daa171a32eaea0d9b017c6 [14] Cravo, R. M. (2008). Controle da expressão do gene ALDH1A2 (RALDH